Healthcare ranking
Top 10 liver cancer clinical trial sponsors 2026
AstraZeneca started the most liver cancer clinical trials as lead sponsor between November 2023 and October 2026, with 6 trials. The list ranks companies worldwide by the number of new interventional trials they lead in this area.
Top 10 at a glance
The full list
| Rank | Company | Headquarters | new industry-sponsored clinical trials (trials) |
|---|---|---|---|
| 1 | AstraZeneca | United Kingdom | 6 |
| 2 | AbbVie | United States | 4 |
| 2 | Akeso | China | 4 |
| 2 | Shanghai Henlius Biotech | China | 4 |
| 5 | CSPC Pharmaceutical Group | China | 3 |
| 5 | Jiangsu Hengrui Pharmaceuticals | China | 3 |
| 5 | Beijing Biotech | China | 3 |
| 5 | Beijing Gene Key Life Technology | China | 3 |
| 5 | BioSyngen | Singapore | 3 |
| 5 | Nanjing Sanhome Pharmaceutical | China | 3 |
| 5 | Zhejiang Haichang Biotech | China | 3 |
How this list is built
We counted interventional clinical trials with a company as lead sponsor and a start date from 1 November 2023 to 31 October 2026 that list liver cancer as a studied condition; withdrawn trials are not counted. Subsidiaries and name variants are merged into the parent company ("CSPC Megalith Biopharmaceutical Co.,Ltd." and "CSPC ZhongQi Pharmaceutical Technology Co., Ltd." are counted as CSPC Pharmaceutical Group), and hospitals, universities and other non-company sponsors are left out. Companies with the same count share a rank, and all companies tied at the last place are shown.
Every position is set by the data alone, by the same rules for every company. Spotted something to update? Write to info@stratummarketresearch.com with the list and the line, and we correct it within two working days.
For ranked companies: a free badge
Ranked companies can show this badge on their website, in a press release or on LinkedIn at no cost. Pick your company, then copy the code.
Frequently asked questions
Who is number one in the liver cancer clinical trial sponsors ranking?
AstraZeneca ranks first with 6 trials (November 2023 to October 2026).
How is this ranking calculated?
We counted interventional clinical trials with a company as lead sponsor and a start date from 1 November 2023 to 31 October 2026 that list liver cancer as a studied condition; withdrawn trials are not counted. Subsidiaries and name variants are merged into the parent company ("CSPC Megalith Biopharmaceutical Co.,Ltd." and "CSPC ZhongQi Pharmaceutical Technology Co., Ltd." are counted as CSPC Pharmaceutical Group), and hospitals, universities and other non-company sponsors are left out. Companies with the same count share a rank, and all companies tied at the last place are shown.
Can a company pay to rank higher?
Positions come only from the counts described above, and inclusion is free. Every company is ranked by the same rules.
How often is the ranking updated?
Every list is recomputed each quarter from the latest public records, and the update date is printed on the page.
Can a ranked company use the badge?
Yes. Every ranked company can use the free web badge on this page on its website, in press releases and on social media.
Custom research
Looking for a specific market?
Tell us the market, the region and the decision you are making. We reply within one working day with a scope and a date.